Trial · NCT04884815
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Stage 1: Incidence of Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs), Treatment-Related TEAEs, and Treatment-Related TESAEs | Up to Week 52 | |
| Primary | Stage 1: Change in 24-hour Urinary Copper Concentration from Baseline at Week 52 | Baseline, Week 52 | |
| Primary | Stage 1: Change in Total Copper from Baseline at Week 52 | Baseline, Week 52 | |
| Primary | Stage 1: Change in Ceruloplasmin-bound Copper from Baseline at Week 52 | Baseline, Week 52 | |
| Primary | Stage 1: Change in Ceruloplasmin from Baseline at Week 52 | Baseline, Week 52 | |
| Primary | Stage 1: Change in Non-Ceruloplasmin-bound Copper (NCC) from Baseline at Week 52 | Baseline, Week 52 | |
| Primary | Stage 1: Change in Free Copper from Baseline at Week 52 | Baseline, Week 52 | |
| Primary | Stage 1: Change in Ceruloplasmin Activity from Baseline at Week 52 | Baseline, Week 52 | |
| Primary | Stage 1: Percent Reduction in Standard of Care (SOC) Medication by Week 52 | Week 52 | |
| Primary | Stage 1: Number of Participants Who Discontinue SOC Medication by Week 52 | Week 52 | |
| Primary | Stage 1: Number of Consecutive Weeks off SOC Medication at Week 52 | Week 52 | |
| Primary | Stage 2: Change in 24-hour Urinary Copper Concentration from Baseline at Week 52, Evaluated for Superiority | Baseline, Week 52 | |
| Primary | Stage 2: Percent Reduction in SOC Medication by Week 52, Evaluated for Superiority | Week 52 | |
| Secondary | Stage 2: Change in Ceruloplasmin Activity Levels from Baseline at Week 52, Evaluated for Superiority | Baseline, Week 52 | |
| Secondary | Stage 2: Number of Participants who Discontinue SOC Medication by Week 52 | Week 52 | |
| Secondary | Stage 2: Change in FACIT-Fatigue Scale Score from Baseline at Week 52 | Baseline, Week 52 | |
| Secondary | Stage 2: Change in Liver Copper Concentration Assessed by Liver Biopsy from Baseline at Week 52 | Baseline, Week 52 | |
| Other | Stage 2: Development of Anti-ATP7B Antibodies | Up to Week 104 | |
| Other | Stage 2: Incidence of TEAEs, TESAEs, AESIs, Treatment-Related TEAEs, and Treatment-Related TESAEs | Up to Week 312 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04884815/registered